Skip to main content
. 2016 Feb 16;34:363–391. doi: 10.1007/s40273-015-0348-x

Fig. 6.

Fig. 6

Cost-effectiveness acceptability curve in terms of cost per quality-adjusted life-year gained. ALAI aripiprazole long-acting injectable, HLAI haloperidol long-acting injectable, OLAI olanzapine long-acting injectable, OO oral olanzapine, PLAI paliperidone long-acting injectable, QALYs quality-adjusted life-years, RLAI risperidone long-acting injectable